Markus McColly

574 total citations · 1 hit paper
12 papers, 408 citations indexed

About

Markus McColly is a scholar working on Genetics, Molecular Biology and Surgery. According to data from OpenAlex, Markus McColly has authored 12 papers receiving a total of 408 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 9 papers in Molecular Biology and 2 papers in Surgery. Recurrent topics in Markus McColly's work include Neurogenetic and Muscular Disorders Research (11 papers), RNA modifications and cancer (4 papers) and CRISPR and Genetic Engineering (3 papers). Markus McColly is often cited by papers focused on Neurogenetic and Muscular Disorders Research (11 papers), RNA modifications and cancer (4 papers) and CRISPR and Genetic Engineering (3 papers). Markus McColly collaborates with scholars based in United States and France. Markus McColly's co-authors include Linda Lowes, Lindsay N. Alfano, Samiah Al-Zaidy, Jerry R. Mendell, Richard Shell, Kelly J. Lehman, M. Iammarino, A. de Kleyn, Matthew N. Meriggioli and Natalie F. Reash and has published in prestigious journals such as Neurology, Molecular Therapy and Journal of the Neurological Sciences.

In The Last Decade

Markus McColly

11 papers receiving 402 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy

2021 173 citations Jerry R. Mendell, Samiah Al-Zaidy et al. JAMA Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Markus McColly United States	5	269	250	165	87	43	12	408
Heike Kölbel Germany	14	444 1.7×	461 1.8×	314 1.9×	84 1.0×	39 0.9×	56	722
A. de Kleyn United States	3	284 1.1×	248 1.0×	150 0.9×	179 2.1×	17 0.4×	8	455
Louise Deschênes Canada	5	298 1.1×	117 0.5×	170 1.0×	40 0.5×	26 0.6×	10	356
Nizar Chahin United States	11	189 0.7×	139 0.6×	53 0.3×	44 0.5×	57 1.3×	21	405
Natalie F. Reash United States	7	214 0.8×	153 0.6×	97 0.6×	83 1.0×	10 0.2×	20	314
Nicole Arrighi France	7	211 0.8×	70 0.3×	50 0.3×	48 0.6×	32 0.7×	12	307
Maria Jędrzejowska Poland	13	297 1.1×	320 1.3×	163 1.0×	65 0.7×	9 0.2×	39	427
Carla Angelozzi Italy	6	453 1.7×	442 1.8×	168 1.0×	79 0.9×	8 0.2×	8	569
Tiziana Vitali Italy	7	462 1.7×	407 1.6×	149 0.9×	81 0.9×	10 0.2×	12	560
Ulrike Schara‐Schmidt Germany	9	157 0.6×	100 0.4×	50 0.3×	42 0.5×	38 0.9×	59	278

Countries citing papers authored by Markus McColly

Since Specialization

Citations

This map shows the geographic impact of Markus McColly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus McColly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus McColly more than expected).

Fields of papers citing papers by Markus McColly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus McColly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus McColly. The network helps show where Markus McColly may publish in the future.

Co-authorship network of co-authors of Markus McColly

This figure shows the co-authorship network connecting the top 25 collaborators of Markus McColly. A scholar is included among the top collaborators of Markus McColly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus McColly. Markus McColly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

1.

Mendell, Jerry R., Samiah Al-Zaidy, Kelly J. Lehman, et al.. (2021). Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy. JAMA Neurology. 78(7). 834–834. 173 indexed citations breakdown →

2.

Shell, Richard, et al.. (2021). S11 Long-term follow-up of the phase 1 START trial of onasemnogene abeparvovec gene therapy in spinal muscular atrophy type 1. A10.1–A10. 2 indexed citations

3.

Mendell, Jerry R., Richard Shell, Kelly J. Lehman, et al.. (2020). SMA – THERAPY. Neuromuscular Disorders. 30. S122–S123. 2 indexed citations

4.

Mendell, Jerry R., Richard Shell, Kelly J. Lehman, et al.. (2020). Gene-Replacement Therapy in Spinal Muscular Atrophy Type 1: Long-Term Follow-Up From the Onasemnogene Abeparvovec-xioi Phase 1/2a Clinical Trial (1808). Neurology. 94(15_supplement). 3 indexed citations

5.

Mendell, J., Richard Shell, Kelly J. Lehman, et al.. (2019). P.351Gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): long-term follow-up from the onasemnogene abeparvovec phase 1/2a clinical trial. Neuromuscular Disorders. 29. S184–S184. 1 indexed citations

6.

Lowes, Linda, Lindsay N. Alfano, W. David Arnold, et al.. (2019). Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement Therapy. Pediatric Neurology. 98. 39–45. 133 indexed citations

7.

McColly, Markus, et al.. (2019). P.066 AVXS-101 gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): long-term follow-up from the phase 1 clinical trial. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 46(s1). S32–S32. 2 indexed citations

8.

Mendell, Jerry R., Richard Shell, Kelly J. Lehman, et al.. (2019). Gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): Long-term follow-up from the onasemnogene abeparvovec phase 1/2A clinical trial. Journal of the Neurological Sciences. 405. 271–271. 4 indexed citations

9.

Mendell, Jerry R., Richard Shell, Kelly J. Lehman, et al.. (2019). Gene-Replacement Therapy (GRT) in Spinal Muscular Atrophy Type 1 (SMA1): Long-Term Follow-Up From the Onasemnogene Abeparvovec Phase 1/2 Clinical Trial. Neuropediatrics. 2 indexed citations

10.

Lowes, Linda, Lindsay N. Alfano, Leslie Nelson, et al.. (2019). P.214Presymptomatic spinal muscular atrophy: reality or myth?. Neuromuscular Disorders. 29. S129–S129.

11.

Mendell, Jerry R., Kelly J. Lehman, Markus McColly, et al.. (2019). AVXS-101 Gene-Replacement Therapy (GRT) in Spinal Muscular Atrophy Type 1 (SMA1): Long-Term Follow-Up From the Phase 1 Clinical Trial (S25.006). Neurology. 92(15_supplement). 6 indexed citations

12.

Mendell, Jerry R., Zarife Sahenk, Samiah Al-Zaidy, et al.. (2017). Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes. Molecular Therapy. 25(4). 870–879. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact